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Objective: To report on the prevalence of isolates with ciprofloxacin resistance in non-typhoidal salmonellas from 
humans in England and Wales in  1997. 
Methods: All non-typhoidal salmonellas referred to  the Laboratory of Enteric Pathogens in  1997 were screened 
for resistance to  ciprofloxacin at 0.125 and 1.0 mg/L and nalidixic acid at 16 mg/L, and results were compared t o  
those for 1994. Full minimal inhibitory concentrations (MICs) of these antimicrobials were also determined for a 
selection of isolates resistant t o  ciprofloxacin at 0.125 mg/L but sensitive at 1.0 mg/L, and for all isolates resistant at 1.0 
mg/L. 
Results: Since 1994 there have been increases in the occurrence of resistance to  ciprofloxacin (MICs: 0.251.0 rng/L) in 
Salmonella enterica serotypes Enteritidis, Typhimurium, Virchow and Hadar. Of particular importance have been 
increases in the occurrence of resistance in  multiresistant S. Typhimurium DT 104, and also in S. virchow, a serotype 
with a propensity for causing extraintestinal infections in  humans. High-level resistance (MIC 22.0 mg/L)was uncommon 
and was identified in only a few strains, all from patients with a history of recent foreign travel. 
Conclusions: There is a strong temporal association between increases in  the occurrence of ciprofloxacin resistance 
in Salmonella serotypes Typhimurium, Virchow and Hadar from humans in  England and Wales and with the licensing 
for use in  food animals in the UK of the related fluoroquinolone antibiotic enrofloxacin; in contrast, for S enteritidis 
ciprofloxacin resistance was most common in  a phage type associated with foreign travel. It is hoped that recent 
recommendations for the use of fluoroquinolone antimicrobials in  food animals in the UK will result in a reduction in 
the occurrence of resistance t o  ciprofloxacin in  zoonotic salmonellas causing infections in  humans. 
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INTRODUCTION 
The Laboratory of Enteric Pathogens (LEP) is the 
national reference center for salmonellas from humans 
for England and Wales and receives strains from public 
health laboratories, National Health Service labora- 
tories and commercial laboratories. All isolates are 
identified by a range of phenotypic methods, including 
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serotyping and, where appropriate, phage typing, and 
are screened for resistance to a panel of antimicrobial 
drugs. As well as being used to supplement serotyping 
and phage typing for epidemiologic investigations, the 
antibiogram data provide a framework for observing 
changes in the incidence of resistance and for investi- 
gating factors contributing to change. 
Two antimicrobials which are included in the panel 
are the quinolone antibiotic nalidixic acid and its 
fluorinated derivative ciprofloxacin. Nalidixic acid is 
rarely used for the treatment of salmonellosis but cipro- 
floxacin is a recognized first-line drug for the treatment 
of invasive salmonellosis in adults [l]. In 1996 we 
reported on the increasing occurrence of resistance to 
ciprofloxacin in salmonellas from humans in England 
and Wales in the 5-year period 1991-94; of particular 
note were significant increases in the occurrence of 
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resistance in Salmonella enterica serotypes Virchow, 
Hadar and Newport [2]. In 1997 we reported on the 
occurrence of resistance in non-typhoidal salmonellas 
from humans in England and Wales in 1996 and 
compared the findings with those for 1994; again, an 
increase in the occurrence of isolates with resistance to 
ciprofloxacin was noted, particularly in S. Typhimurium, 
S. Hadar and S. Virchow [3]. 
In both these studies the levels at which resistance 
to ciprofloxacin was tested for were 0.125 and at 
1.0 mg/L. Although the majority of ciprofloxacin- 
resistant salmonellas were resistant at 0.125 mg/L but 
not at 1.0 mg/L, in a few isolates the levels of resistance 
were greater than 1.0 mg/L. The recommended 
breakpoint for the testing of Enterobacteriaceae for 
resistance to ciprofloxacin is 1.0 mg/L [4]. However, 
although resistance below this level is not regarded as 
clinically significant, there have been several reports of 
treatment failures in cases of invasive salmonella infec- 
tions in which the ciprofloxacin MIC has been below 
the recognized serum level of the antibiotic following 
treatment at  the recommended dosage [5-81. It has also 
been reported that borderline susceptibility to 
ciprofloxacin in vitro may prehct treatment failure and 
the development of full resistance [9], and because of 
this the determination of the MIC of ciprofloxacin for 
isolates that show reduced susceptibility on disk testing 
has been recommended. Because of these recommend- 
ations and because of the possibility of treatment 
failures at levels below 1 .O mg/L, we have continued to 
screen for resistance to ciprofloxacin at both 0.125 and 
1.0 mg/L. 
We now provide an update on the occurrence of 
resistance to ciprofloxacin in salmonellas isolated from 
humans in England and Wales in 1997, with particular 
reference to multiresistant S Typhimurium definitive 
phage type (DT) 104 (=DT 104), epidemic in humans 
and food animals in the UK since 1990 [lo-121, and 
the zoonotic serotypes Enteritidis, Virchow and Hadar. 
MATERIALS AND METHODS 
All salmonellas received in the LEP in 1997 were 
identified by serotyping when appropriate [13], and the 
epidemiologically important serotypes S. Enteritidis, S. 
Typhimurium, S. Virchow and S. Hadar were further 
subdivided by phage typing [14-191. All isolates were 
screened for resistance to ampicillin, chloramphenicol, 
gentamicin, kanamycin, streptomycin, sulfonamides, 
tetracyclines, trimethoprim, furazolidone, nalidixic acid 
and ciprofloxacin, using an agar dilution breakpoint 
method in Isosensitest agar [20]. The final plate con- 
centrations of the respective antibiotics were (mg/L): 
ampicillin, 8 and 128; chloramphenicol, 8; gentamicin, 
4; kanamycin, 16; streptomycin, 16 and 128; sulfon- 
amides, 64; tetracyclines, 8 and 128; trimethoprim, 2; 
nalidixic acid, 16; ciprofloxacin, 0.125 and 1.0. Full 
minimal inhibitory concentrations (MICs) of nalidixic 
acid and ciprofloxacin, based on growth of cultures on 
doubling dilutions of the respective antibiotics in 
Isosensitest agar, were also determined for five 
randomly chosen isolates of S. Enteritidis, 18 of S. 
Typhimurium (including 15 of multiresistant S. 
Typhimurium DT 104), four of S. Virchow and four 
of S. Hadar resistant to ciprofloxacin at 0.125 mg/L but 
sensitive at 1.0 mg/L, and for all isolates resistant at  
1 .O mg/L. 
Overall occurrence of resistance to ciprofloxacin 
In 1997 the four most common serotypes of S. enterica 
from humans in England and Wales were Enteritidis, 
Typhimurium, Virchow and H& comprising 89% of 
isolates identified (Table 1). For S. Enteritidis, 1.3% of 
the isolates were resistant to ciprofloxacin at 0.125 
mg/L, which is a three-fold increase since 1994. For S. 
Typhiinurium, the occurrence of ciprofloxacin- 
resistant isolates increased in 1997 from 1% to 13%, for 
S. Virchow from 5% to 14% and for S. Hadar from 40% 
to 50%. For the remaining 230+ serotypes, the overall 
occurrence of ciprofloxacin resistance has increased 
from 1% to 3% since 1994, but because of the low 
numbers involved, the significance of the results for 
individual serotypes is difficult to assess and will not be 
discussed further in this paper. 
Table 1 Resistance to ciprofloxacin in Salmonella serotypes 
Enteritidis, Typhimurium, Virchow and Hadar isolated 
from humans in England and Wales in 1994 and 1997 
Percentage 
Total ciprofloxacin 
Serotype Year received resistant” 
S. Enteritidis 1994 
1997 
S. Typhirnurium 1994 
1997 
S. Virchow 1994 
1997 
S. Hadar 1994 
1997 
Others 1994 
1997 
17 701 
22 723b 
5 603 
4 690b 
2 797 
704b 
753 
692b 
4 293 
3 31jb 
0.4 
1.3 
1 
10 
5 
14 
40 
50 
1 
3 
“MIC: 20.25 mg/L. 
bProvisional figures. 
AU isolates resistant to ciprofloxacin with MICs 20.25 mg/L were 
also resistant to nalidixic acid with MICs 2256 mg/L. 
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Only three isolates were identified which were 
resistant to ciprofloxacin at 1.0 mg/L. These isolates, 
which were all of serotype Typhimurium, did not react 
with the S. Typhimurium typing phages and were 
therefore designated as untypeable. All three isolates 
were from patients with a history of recent return from 
countries outside the UK. 
Table 2 MICs of ciprofloxacin and nalidixic acid for 
salmonellas with resistance to ciprofloxacin at 0.125 mg/L 
MICs (mg/L) 
Serotype/ No. 
Phage type tested Ciprofloxacin Nalidixic acid 
S. Enteritidis 5 0.5 (3) 
1.0 (2) 
S. Typhimurium 
DT 104 15 0.5-1.0 (15) 
Others 6 0.5-1.0 (3) 
36 (2) 
32 (1) 
S. Virchow 4 0.5-1.0 (4) 
S. Hadar 4 0.5-1.0 (4) 
256 (3) 
512 (2) 
512 (15) 
512 (l), 1024 (1) 
1024 (1) 
512 (4) 
512 (4) 
256-512 (3) 
In parentheses are numbers of isolates with resistance at the 
specified MICs. 
Minimal inhibitory concentrations of ciprofloxacin and 
nalidixic acid 
For the 31 strains resistant to ciprofloxacin at 
0.125 mg/L but sensitive at 1.0 mg/L which were 
subjected to full MIC determination, the MICs of 
ciprofloxacin ranged from 0.5 to 1.0 mg/L, and of 
nalidixic acid from 256 to 512 mg/L (Table 2). The 
corresponding MICs for the three isolates of S. 
Typhimurium with high-level resistance to cipro- 
floxacin ranged from 32 to 64 mg/L for ciprofloxacin, 
and fi-om 512 to 1024 mg/L for nalidixic acid. 
Distribution of ciprofloxacin-resistant strains within phage 
tVPe 
The distribution of phage types of S. Enteritidis, S. 
Typhimurium, S. Virchow and S. Hadar with isolates 
resistant to ciprofloxacin is presented in Table 3. 
S. Enteritidis 
For S. Enteritidis, resistance to ciprofloxacin was ob- 
served in 14 of 45 phage types (PTs) identified in 1997. 
Resistance was most common in PT1, and in this phage 
type 19% of isolates were ciprofloxacin resistant. In 
contrast, for PT4, less than 0.5% of isolates were 
Table 3 Distribution of resistance to ciprofloxacin within phage type in Salmonella serotypes Enteritidis, Typhimurium, 
Virchow and Hadar, 1997 
Phage types with ciprofloxacin resistance 
No. of phage No. of Percentage 
Serotype types identified PT isolatesa ciprofloxacin resistant 
S. Enteritidis 45 1 928 19 
6a 1137 14 
4 15 210 0.4 
6 1669 0.4 
Others 3 779 0.6 
(10 PTs) 
S. Typhimurium 
S. Virchow 
S. Hadar 
90 
25 
23 
104 
104b 
U302 
193 
Others 
(4 PTs) 
45 
31 
26 
8 
Others 
(5 PTs) 
21 
2 
9 
Others 
(13 PTs) 
2 956 
240 
206 
286 
1 002 
31 
38 
222 
191 
222 
17 
268 
83 
324 
14 
5 
4 
3 
0.3 
68 
29 
21 
8 
3 
94 
80 
10 
28 
'Provisional figures. 
PT, phage type. 
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resistant to ciprofloxacin. For both PT1 and PT4, 
ciprofloxacin resistance was commonly present as a 
single resistance and was rarely identified in combin- 
ation with other resistances. 
S. Typhimurium 
For S. Typhimurium, ciprofloxacin resistance was 
observed in nine of 90 phage types but was most 
common in multiresistant D T  104 (Table 3). In this 
phage type, 14% of isolates were resistant to this 
antimicrobial. This should be compared to 1994, when 
only 0.6% of isolates of D T  104 were resistant [ l l ] .  
Resistance to ciprofloxacin was also common in the 
related multiresistant phage types D T  104b and U302 
but was rare in other phage types. 
S. Virchow 
Resistance to ciprofloxacin was observed in nine of 25 
phage types, sometimes as a single resistance but more 
commonly together with other resistances. The phage 
types in which resistance was most common were 
PT45, PT31 and PT26, with 68%, 29% and 21% of 
isolates being ciprofloxacin resistant. 
S, Hadar 
For S. Hadar, ciprofloxacin resistance was observed in 
16 of 23 phage types, most commonly in combination 
with at least two other resistances. The phage types in 
which resistance was most common were PT2, PT21 
and PT9, with 80%, 94% and 10% of isolates being 
resistant. However, it is noteworthy that none of the 
isolates of PT5, the second most common S. Hadar 
phage type in 1997, were resistant to ciprofloxacin. 
DISCUSSION 
Since 1994, the occurrence of ciprofloxacin resistance 
has increased in the four most common salmonella 
serotypes from cases of human infection in England 
and Wales-Enteritidis, Typhimurium, Virchow and 
Hadar. For S. Enteritidis, resistance was most common 
in PT1, which is a phage type often associated with 
travel to countries in southern Europe. This should be 
contrasted with PT4, a phage type which is endemic 
in the UK and for which less than 0.5% of isolates were 
ciprofloxacin resistant. 
For S. Typhimurium, the overall occurrence of 
ciprofloxacin resistance has increased from 1% to 10% 
since 1994. Resistance to this antimicrobial was most 
common in multiresistant D T  104, and in this phage 
type increased from 0.6% in 1994 to 13% in 1997. Data 
from the Veterinary Laboratory Agencies [12] have 
demonstrated that DT 104 with resistance to nalidixic 
acid is now common in turkeys, chickens and cattle. 
Data for resistance to ciprofloxacin or to the veterinary 
equivalent enrofloxacin were not provided, but recent 
reports from Piddock et al [21] and from Ridley and 
Threlfdl [22] have demonstrated that food animal 
isolates of S. Typhimurium D T  104 with resistance to 
nalidixic acid are also resistant to ciprofloxacin at the 
levels described above. As S. Typhimurium DT 104 is a 
zoonotic pathogen, it is possible that food animals, and 
particularly poultry and cattle, are important sources of 
ciprofloxacin-resistant strains of this phage type in cases 
of human infection. S. Virchow and S. Hadar are also 
poultry-related serotypes [12] and it is also possible that 
poultry may have been an important source of cipro- 
floxacin resistant strains of these serotypes. The high 
incidence of resistance to ciprofloxacin in S. Virchow is 
of particular concern because of the propensity of this 
serotype for extraintestinal spread in humans [23]. 
One drug which has been extensively used in food 
animals in the UK since 1994 is the fluoroquinolone 
antibiotic enrofloxacin, which was approved for 
veterinary use in the UK in November 1993. Strains 
resistant to enrofloxacin show decreased susceptibility 
to ciprofloxacin, and it is possible that the use of this 
antimicrobial in food animals has contributed to the 
increases in the occurrence of ciprofloxacin resistance 
in zoonotic salmonellas from cases of human infection. 
In 1992 the Expert Group on Animal Feedingstuffs 
recommended that ‘not only should antibiotics giving 
cross-resistance to those in human medicine not be 
used as growth promoters but . . . their prophylactic use 
in animals be reconsidered’ [24]. This recommend- 
ation, which was particularly relevant to fluoroquin- 
olone antibiotics such as enrofloxacin, was not put into 
practice. However, a recent report by the House of 
Lords Select Committee on Science and Technology 
has recommended the rapid introduction by the 
veterinary profession of a code of practice on when 
fluoroquinolone antibiotics should be prescribed for 
food animals [25]. This has already been accepted by 
some pharmaceutical companies, and recently intro- 
duced recommendations for the use of enrofloxacin in 
livestock are encouraging. In light of a recent report 
from Denmark describing a lack of clinical response to 
fluoroquinolone antibiotics in patients infected with 
multiresistant S. Typhimurium D T  104 with additional 
resistance to quinolones in an outbreak associated with 
pork of Danish origin [8], it is hoped that these 
recommendations will rapidly be implemented. 
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